“Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 5, Sept. 2020, p. s39, https://doi.org/10.25251/skin.4.supp.39.